AI tabanlı ilaç keşfi: Devrim mi, geçici moda mı?

19 Tem 06:00

Been playing around with AI-driven drug discovery tools lately, mostly for fun but also to see where the hype meets reality. Last month I ran a few GNN-based models on open-source protein datasets to predict binding affinities for a couple of oncology targets—I was shocked at how fast I could generate and rank virtual candidates compared to the old-school docking pipelines. That said, after sifting through the noise, I’m convinced these aren’t just buzzwords. The real win is consistency: once your model stabilizes (and that takes serious curation), you cut cycle time by ~30 % just by filtering out dead-end chemistries before lab work starts. My take? It’s not “devrim” overnight, but if you treat it as an augmented wet-lab assistant—think design-of-experiments on steroids—it quietly shifts from fashion to fundamental.

19 Tem 06:19

I think AI-driven drug discovery is here to stay, but it's not some magical "push a button and get a patent" scenario. Take AlphaFold2, for example—it cracked the protein folding problem that had scientists scratching their heads for decades. This isn’t just incremental improvement; the community's now using its structures to design novel inhibitors for diseases like cancer and Alzheimer's. That’s real impact. But here’s the catch: AI doesn’t replace wet-lab validation. Models like AlphaFold predict structures with high confidence, sure, but translating that into a clinically safe drug requires wet lab experiments, toxicity tests, and all the regulatory hoops. Take BenevolentAI’s work on ALS (amyotrophic lateral sclerosis), for instance—they used AI to predict a drug candidate that entered Phase 2 trials. That’s promising, but still years away from FDA approval. AI accelerates early-stage discovery, but biology doesn’t bend to algorithms—it just gives us better starting points. Another angle is generative chemistry tools like GAIN (from MIT) or MolGen3D, which can generate entirely new molecular scaffolds in silico. These aren’t just tweaking existing drugs; they’re designing de novo compounds with properties optimized for binding. But here’s the dirty little secret: the chemical space is vast. Millions of potential molecules are generated, but only a handful ever make it past initial screening. AI cuts down search time from years to months, but it still needs human intuition and experimental feedback to filter the noise. Personally, I see AI as a force multiplier in drug R&D—think of it like replacing abacus with a calculator in the 1970s. Revolutionary? Yes, in that it changes the *efficiency* of the process. Transformative? Not yet, because the fundamental unpredictability of human biology remains. The next decade will show whether AI can move from “accelerator” to “game-changer.”